The Chemours Company (NYSE:CC – Get Free Report) gapped down prior to trading on Wednesday after BMO Capital Markets lowered their price target on the stock from $34.00 to $27.00. The stock had previously closed at $17.48, but opened at $16.72. BMO Capital Markets currently has an outperform rating on the stock. Chemours shares last traded at $17.16, with a volume of 145,724 shares.
A number of other equities analysts also recently weighed in on the company. Morgan Stanley cut their target price on Chemours from $25.00 to $22.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Barclays lifted their price target on shares of Chemours from $21.00 to $23.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 5th. Truist Financial initiated coverage on shares of Chemours in a report on Tuesday, January 28th. They set a “buy” rating and a $27.00 target price on the stock. The Goldman Sachs Group decreased their price target on shares of Chemours from $24.00 to $21.00 and set a “neutral” rating on the stock in a report on Tuesday, January 7th. Finally, Mizuho cut their target price on shares of Chemours from $22.00 to $21.00 and set a “neutral” rating for the company in a research report on Tuesday, January 7th. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $23.56.
Read Our Latest Stock Report on Chemours
Institutional Trading of Chemours
Chemours Trading Down 4.1 %
The stock has a market capitalization of $2.51 billion, a P/E ratio of 29.42 and a beta of 1.81. The firm’s 50 day moving average price is $18.13 and its 200 day moving average price is $18.93. The company has a debt-to-equity ratio of 6.70, a current ratio of 1.68 and a quick ratio of 0.92.
Chemours (NYSE:CC – Get Free Report) last released its quarterly earnings results on Tuesday, February 18th. The specialty chemicals company reported $0.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.10 by $0.01. Chemours had a net margin of 1.51% and a return on equity of 26.54%. The company had revenue of $1.36 billion during the quarter, compared to the consensus estimate of $1.37 billion. As a group, equities research analysts expect that The Chemours Company will post 2.06 earnings per share for the current fiscal year.
Chemours Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Friday, March 14th. Investors of record on Friday, February 28th will be paid a $0.25 dividend. This represents a $1.00 dividend on an annualized basis and a yield of 5.96%. The ex-dividend date of this dividend is Friday, February 28th. Chemours’s payout ratio is currently 175.44%.
Chemours Company Profile
The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.
Featured Stories
- Five stocks we like better than Chemours
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- 3 Stocks Poised to Thrive as NVIDIA Dominates the AI Boom
- What Are Dividend Champions? How to Invest in the Champions
- MercadoLibre: High-Growth EM Stock With 100% Upside Potential
- What Are Trending Stocks? Trending Stocks Explained
- As the Magnificent 7 Stalls, These 3 Stocks Are Gaining Momentum
Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.